EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives
In the last decade the limited treatment options for patients with metastatic soft tissue sarcoma have expanded considerably. With the addition of olaratumab to first-line treatment with doxorubicin, the introduction of several new agents in second-line treatment and beyond and other promising agents in the pipeline, perspectives of patients with metastatic soft tissue sarcoma are improving. Due to increasing insight into the biology of the different soft tissue sarcoma subtypes, choice of treatment has become much more histology-driven, although more prognostic and predictive factors are needed to further personalise therapy. This report summarises the current state of the art and discusses the promising developments in the treatment of patients with metastatic soft tissue sarcoma.
|Keywords||Chemotherapy, Immunotherapy, Metastatic soft tissue sarcoma, Soft tissue sarcoma, Systemic treatment|
|Persistent URL||dx.doi.org/10.1016/j.ejca.2017.10.020, hdl.handle.net/1765/103336|
|Journal||European Journal of Cancer|
Vos, M, & Sleijfer, S. (2018). EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives. European Journal of Cancer, 88, 87–91. doi:10.1016/j.ejca.2017.10.020